New oral anticoagulant approved

Apixaban is set to launch in the UK after being approved by European regulators.

By inhibiting factor Xa and prothrombinase, apixaban prevents thrombin-induced platelet aggregation.
By inhibiting factor Xa and prothrombinase, apixaban prevents thrombin-induced platelet aggregation.

The direct factor Xa inhibitor is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. It will be marketed as Eliquis.

 "The approval of Eliquis gives European orthopaedic surgeons a new option in VTE prevention that is more effective than the current standard of care, enoxaparin 40mg once daily, and importantly, without increasing bleeding," said Dr Michael Rud Lassen of Glostrup Hospital in Copenhagen, Denmark, lead investigator for two Phase III trials of apixaban in orthopaedic surgery.

The randomised double-blind Phase III studies compared oral apixaban 2.5mg twice daily with subcutaneous enoxaparin 40mg once daily. ADVANCE-2 enrolled 3057 patients scheduled for knee replacement surgery and ADVANCE-3 enrolled 5407 patients undergoing hip replacement. Treatment continued for 10–14 days after knee replacement and for 35 days after hip replacement.

The primary efficacy end point in both trials was a composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, and death from any cause during treatment.

In ADVANCE-2, 1973 patients were eligible for the efficacy analysis. The primary end point occurred in 15% of the apixaban group and 24% of the enoxaparin group, representing a relative risk reduction of 38% for apixaban (95% CI 26—49%; p<0.0001).

Similarly, among the 3866 patients evaluable for efficacy in ADVANCE-3, the primary end point occurred in 1.4% of those who received apixaban compared with 3.9% of those given enoxaparin – a relative risk reduction of 64% (95% CI 46—78%; p<0.001).

Rates of major or clinically relevant non-major bleeding were comparable for apixaban and enoxaparin in both trials.

Apixaban will join dabigatran and rivaroxaban as potential replacements for low molecular-weight heparins, the current standard of care for VTE prevention after joint replacement.

Co-developers Bristol-Myers Squibb and Pfizer are also testing apixaban in a Phase III trial for stroke prevention in atrial fibrillation.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Pradaxa: safety update owing to risk of serious haemorrhage

Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant...

NICE approves dabigatran in atrial fibrillation

NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed...

Eliquis: new oral anticoagulant

Eliquis: new oral anticoagulant

Eliquis (apixaban), an oral factor Xa inhibitor, has...

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa (dabigatran) is now licensed for the prevention...

Apixaban 'better than aspirin' in atrial fibrillation

Apixaban 'better than aspirin' in atrial fibrillation

Researchers have stopped a Phase III trial of a new...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases